Onderneming Wayland Group Corp Canadian Securities Exchange
Aandelen
CA5667241007
Farmaceutische producten
Vakgebied
Verkoop per activiteit
USD in miljoen | 2016 | Gewicht | 2017 | Gewicht | Delta |
---|---|---|---|---|---|
Marijuana Production for Medical Purposes
100,0
%
| 3 | 100,0 % | 2 | 100,0 % | -18,98% |
Verkoop per regio
USD in miljoen | 2016 | Gewicht | 2017 | Gewicht | Delta |
---|---|---|---|---|---|
Canada
100,0
%
| 3 | 100,0 % | 2 | 100,0 % | -18,98% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Dan Healey
COO | Chief Operating Officer | - | - |
Steven Bennett
CTO | Chief Tech/Sci/R&D Officer | - | - |
Compliance Officer | - | - | |
Geoff Kosar
SAM | Sales & Marketing | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 237 260 499 | 237 260 499 ( 100,00 %) | 0 | 100,00 % |
Bedrijfsgegevens
Wayland Group Corp.
845 Harrington Court Unit 3
L7N 3P3, Burlington
+289-288-6274
![Adres Wayland Group Corp](https://cdn.zonebourse.com/static/address/34637464.png)
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+27,29% | 5,56 mld. | |
-33,07% | 3,55 mld. | |
-3,24% | 3,01 mld. | |
-24,56% | 2,64 mld. | |
-10,17% | 2,3 mld. | |
+46,81% | 1,95 mld. | |
+48,03% | 1,52 mld. | |
-11,69% | 1,45 mld. | |
+43,81% | 1,38 mld. |